Question 1

What is the difference between Verzenio and Kisqali?

Accepted Answer

Verzenio is Abemaciclib inhibits CDK4 and CDK6, blocking Rb phosphorylation and G1/S cell cycle progression. and is developed by Eli Lilly. Kisqali is Ribociclib inhibits CDK4/6 kinases to arrest G1 cell cycle phase; letrozole inhibits aromatase to reduce estrogen biosynthesis. and is developed by Novartis.

Question 2

What are Verzenio and Kisqali used for?

Accepted Answer

Verzenio: Hormone receptor positive malignant neoplasm of breast, Human epidermal growth factor 2 negative carcinoma of breast. Kisqali: Hormone receptor positive malignant neoplasm of breast.

Question 3

Are Verzenio and Kisqali in the same drug class?

Accepted Answer

No — Verzenio is Kinase inhibitor and Kisqali is CDK4/6 inhibitor; aromatase inhibitor.

	Verzenio	Kisqali
Generic name	abemaciclib	ribociclib
Sponsor	Eli Lilly	Novartis
Drug class	Kinase inhibitor	CDK4/6 inhibitor; aromatase inhibitor
Molecular target	Cyclin-dependent kinases 4 and 6 (CDK4/CDK6)	Cyclin-dependent kinase (CDK) 4 and 6; aromatase enzyme
Phase	FDA-approved	FDA-approved
Therapeutic area	Oncology	Oncology
First approval	2017	2017

Verzenio vs Kisqali

At a glance

Mechanism of action

Approved indications

Verzenio

Kisqali

Common side effects

Verzenio

Kisqali

Further reading

Verzenio	Abemaciclib inhibits CDK4 and CDK6, blocking Rb phosphorylation and G1/S cell cycle progression.
Kisqali	Ribociclib inhibits CDK4/6 kinases to arrest G1 cell cycle phase; letrozole inhibits aromatase to reduce estrogen biosynthesis.